SCHEMBL20384682

SCHEMBL20384682

CCC(C)CCCN1CCN(C)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.40
USP2 O75604 2/20 0.39
SIGMAR1 Q99720 2/20 0.38
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
CSNK2A3 Q8NEV1 1/20 0.36
GNAI3 P08754 2/20 0.35
GNAO1 P09471 2/20 0.35
GNAI1 P63096 2/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
MAPT P10636 1/20 0.33
KDM1A O60341 1/20 0.33
TP53 P04637 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21120546 0.94 PAOX (0.43) PAOXUSP2SIGMAR1CSNK2A2CSNK2B
SCHEMBL13555441 0.88 USP2 (0.34) PAOXUSP2
SCHEMBL20227876 0.88 USP2 (0.36) USP2GNAI3GNAO1GNAI1ALDH1A1
SCHEMBL18911024 0.87 SIGMAR1 (0.35) PAOXUSP2SIGMAR1CSNK2A2CSNK2B
SCHEMBL21981137 0.86 PAOX (0.39) PAOXUSP2SIGMAR1CSNK2A2CSNK2B
SCHEMBL20332097 0.85 HRH3 (0.46) ALDH1A1MAPTSMN1; SMN2
SCHEMBL13089689 0.85 HRH3 (0.41) USP2ALDH1A1MAPTSMN1; SMN2
SCHEMBL24065813 0.84 KEAP1 (0.44) SIGMAR1GNAI3GNAO1GNAI1SMN1; SMN2
SCHEMBL21348734 0.83 HRH3 (0.50) MAPTSMN1; SMN2
SCHEMBL24975389 0.82 GNAI3 (0.37) USP2GNAI3GNAO1GNAI1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399303-A1 Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same UNIV YALE (US) 2023-12-14 US disclosed
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy THE JOHNS HOPKINS UNIVERSITY (US) 2023-07-11 US disclosed
WO-2023077150-A1 POLYMERS AND NANOPARTICLES FOR INTRAMUSCULAR NUCLEIC ACID DELIVERY THE JOHNS HOPKINS UNIVERSITY (US) 2023-05-04 WO disclosed
US-20230002790-A1 POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
US-20220154219-A1 GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS THE JOHNS HOPKINS UNIVERSITY 2022-05-19 US disclosed
US-10968198-B2 Biaryltriazole inhibitors of macrophage migration inhibitory factor YALE UNIVERSITY (US) 2021-04-06 US disclosed
US-20200140831-A1 TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY THE JOHNS HOPKINS UNIVERSITY 2020-05-07 US disclosed
US-20190276425-A1 BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR UNIV YALE (US) 2019-09-12 US disclosed
US-10336721-B2 Biaryltriazole inhibitors of macrophage migration inhibitory factor YALE UNIVERSITY (US) 2019-07-02 US disclosed
EP-3102577-B1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2018-07-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10968198-B2 Biaryltriazole inhibitors of macrophage migration inhibitory factor MIF, MMP12, CSF1R PAOX 1249/4885USP2 2027/4885SIGMAR1 4096/4885
US-10336721-B2 Biaryltriazole inhibitors of macrophage migration inhibitory factor MIF, MMP12, CSF1R PAOX 1249/4885USP2 2027/4885SIGMAR1 4096/4885
US-20220154219-A1 GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS PBK, MICA, STAT3 PAOX 4460/4885USP2 1654/4885SIGMAR1 3739/4885
US-20190276425-A1 BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR MIF, MMP12, CSF1R PAOX 1249/4885USP2 2027/4885SIGMAR1 4096/4885
US-11697804-B2 Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy POLRMT, HDGF, PCNP PAOX 1246/4885USP2 2724/4885SIGMAR1 1370/4885
US-20200140831-A1 TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY POLRMT, HDGF, PCNP PAOX 1246/4885USP2 2724/4885SIGMAR1 1370/4885
US-20230399303-A1 Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same MIF, MMP12, METAP1 PAOX 3639/4885USP2 873/4885SIGMAR1 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.